Beta Finch - S&P 100 - EN

More earnings analysis: https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
# Beta Finch Podcast Script: Zoetis Q1 2026 Earnings

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into quarterly results to help you understand what's really happening in the market. I'm Alex.

**JORDAN:** And I'm Jordan. Before we dig in, this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**ALEX:** Today we're breaking down Zoetis' Q1 2026 earnings - and wow, this was a quarter that really caught investors off guard. Jordan, what's your first take on these numbers?

**JORDAN:** Alex, this was definitely a reality check for the animal health giant. On the surface, flat organic operational revenue growth doesn't look terrible, but when you peel back the layers, there's a lot more going on here. They had about $100 million in sales that shifted from Q4 2025 into Q1 due to fiscal year alignment changes. Without that boost, they would have seen a 5% organic operational decline.

**ALEX:** That's a significant difference. And CEO Kristin Peck was pretty candid about what went wrong, wasn't she?

**JORDAN:** Absolutely. She laid out four key factors that created what she called "a convergence of interconnected dynamics." First, rising prices at veterinary clinics led to lower clinic traffic - pet owners are feeling the pinch. Second, those same pet owners are showing increased price sensitivity, especially for premium products where Zoetis leads. Third, competition intensified across key categories like dermatology and parasiticides, with competitors using aggressive pricing. And fourth - this is crucial - these competitive launches didn't expand the overall market like they have historically.

**ALEX:** That last point seems really important. Historically, when new competitors entered Zoetis markets, the pie got bigger for everyone. But not this time?

**JORDAN:** Exactly. In the past, competition actually helped grow markets - think about how the parasiticide market expanded when new players came in. But this time, with pet owners being more price-conscious and visiting clinics less frequently, new entrants are just taking share from existing players rather than bringing new customers into the market.

**ALEX:** Let's talk specific numbers. How did their key franchises perform?

**JORDAN:** The companion animal business really struggled, particularly in the U.S. where it declined 11%. Their key dermatology franchise - which includes blockbusters like Apoquel and Cytopoint - fell 11% globally to $347 million. The Simparica parasiticide franchise was down 1% to $385 million globally, but that masks an 8% decline in the U.S. And their OA Pain products, Librela and Solensia, dropped 8% combined to $140 million.

**ALEX:** But it wasn't all bad news, right? I noticed livestock performed well.

**JORDAN:** That's the silver lining here. Livestock delivered 12% organic operational growth to $720 million, with broad-based strength across cattle, poultry, and swine. Favorable producer economics and strong protein demand are driving investment in herd health. It really shows the value of Zoetis' diversified portfolio - when companion animal struggles, livestock can pick up some slack.

**ALEX:** What about guidance? I imagine they had to adjust expectations.

**JORDAN:** They definitely had to recalibrate. Full-year revenue growth guidance came down to 2-5% from what was presumably higher expectations, and adjusted net income growth is now expected at 2-6%. CFO Wetteny Joseph noted that while the fiscal year alignment was supposed to provide a 200-250 basis point tailwind, the challenging operating environment more than offset that benefit.

**ALEX:** During the Q&A, there were some pointe

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: RETAIL (https://betafinch.com/groups/RETAIL), INCOME (https://betafinch.com/groups/INCOME)
──────────
# Beta Finch Podcast Script: McDonald's Q1 2026 Earnings

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and with me as always is Jordan. Today we're diving into McDonald's Q1 2026 results, and wow, there's a lot to unpack here. Jordan, before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN**: Thanks Alex, and yeah - McDonald's certainly delivered some interesting headlines this quarter. On the surface, the numbers look pretty solid - global comparable sales up 3.8%, system-wide sales growing 6% in constant currency. But when you dig deeper, there are some real challenges brewing beneath those golden arches.

**ALEX**: Absolutely. Let's start with the good news. The U.S. business showed resilience with 3.9% comparable sales growth, and they're gaining market share in nearly all their top 10 markets globally. That's impressive in this environment. But Jordan, what really caught my attention was CEO Chris Kempczinski's emphasis on their "3 for 3" strategy - value, marketing, and menu innovation.

**JORDAN**: Right, and the value piece is particularly crucial here. They've completely revamped their McValue platform with unanimous franchisee support - that's key. We're talking about items under $3 and a new $4 breakfast meal deal. Kempczinski was pretty emphatic about this, saying "McDonald's is not going to get beat on value and affordability."

**ALEX**: That's a bold statement, but they're backing it up with action. What's interesting is they're applying lessons from international markets back to the U.S. Most of their major international markets already had this dual approach - both everyday affordable items and meal bundles. France was apparently the exception, which might explain some of their struggles there.

**JORDAN**: Speaking of struggles, let's talk about the elephant in the room - those U.S. company-operated store margins. CFO Ian Borden was brutally honest, calling them "not acceptable." That's pretty remarkable transparency from a major corporation.

**ALEX**: It really is. And when you connect the dots, this ties into a bigger strategic question about McDonald's ownership structure. They're essentially saying some of their franchisees are running restaurants better than McDonald's corporate is running their own locations. That's... not ideal.

**JORDAN**: Exactly. And it sounds like they're seriously considering refranchising more company-operated stores. Kempczinski said they're "always looking to put restaurants in the hands of the best operator," which is diplomatic corporate-speak for "we might be selling these to franchisees who can run them better."

**ALEX**: Let's shift to international markets for a moment. The UK really stood out as a success story - they're on their third consecutive quarter of market share gains with mid-to-high single-digit comp growth. Jordan, what's working there?

**JORDAN**: It's that same formula - they introduced something called "Meal Deal Plus" for £5.59, which gives customers more flexibility. Plus they're executing well on marketing campaigns like the "Friends" TV show promotion. Australia's another bright spot using similar tactics. But then you have France struggling, which shows this isn't automatic - you have to execute consistently.

**ALEX**: And speaking of execution, they're rolling out their new beverage platform globally. Yesterday, all U.S. restaurants started offering refreshers and crafted sodas under the McCafe brand, with Red Bull-infused energy drinks coming later this year.

**JORDAN**: That timing on Red Bull is interesti

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
──────────
**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into AppLovin's absolutely explosive Q1 2026 earnings call. Jordan, before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN**: Thanks Alex, and wow - what a quarter to analyze! AppLovin just delivered numbers that honestly feel almost too good to be true. We're talking about a company that beat guidance across every single metric while posting 59% year-over-year revenue growth. That's not a typo, folks - fifty-nine percent growth on a $1.84 billion revenue base.

**ALEX**: It's absolutely mind-blowing when you think about it. Most companies this size would be thrilled with double-digit growth, and here's AppLovin growing at nearly 60%. But Jordan, what really caught my attention was the margin expansion story. They hit an 85% adjusted EBITDA margin - that's up 400 basis points from last year.

**JORDAN**: The margin story is incredible, Alex. They're generating $1.56 billion in adjusted EBITDA, which represents 86% flow-through from revenue to EBITDA quarter-over-quarter. That kind of operational leverage is just extraordinary. And they're converting that into serious cash - $1.29 billion in free cash flow for the quarter.

**ALEX**: Now let's talk about the elephant in the room - or should I say the rocket ship in the room. CEO Adam Foroughi spent most of his time talking about their upcoming June launch where they're opening their Axon platform to the public for the first time in 14 years. Jordan, help our listeners understand why this is such a big deal.

**JORDAN**: This is potentially transformative, Alex. For over a decade, AppLovin has been a closed platform - meaning only select partners could access their advertising technology. Starting in June, any advertiser globally can sign up and start running campaigns. Foroughi called it "a major milestone" that "changes the trajectory of this company in a very meaningful way."

**ALEX**: And the timing seems perfect because their consumer vertical - that's everything outside of gaming - is absolutely on fire. It grew roughly 25% from January to March alone, and April set a record month that exceeded even their peak Q4 performance. Remember, most advertising businesses see a massive drop from Q4 to Q1, but AppLovin is actually growing through that seasonal headwind.

**JORDAN**: What's fascinating is how early this consumer business still is - Foroughi emphasized it's only 18 months old! Yet it's scaling at a pace that gets the management team "very excited." He shared this incredible example of an Israeli cookware company that went from $4 million in revenue to projecting $80 million, with most of their ad spend on AppLovin's platform.

**ALEX**: That's the kind of success story they want to "replicate thousands of times over," as Foroughi put it. But let's not forget about gaming, which is still the foundation of everything they do. The gaming business continues to grow at these exceptional rates, and there's this interesting shift happening where games that historically only made money from in-app purchases are now testing hybrid models that include advertising.

**JORDAN**: That hybrid monetization trend could be huge, Alex. Foroughi explained that when a puzzle game company realizes a cookware brand isn't their competition, they're suddenly open to showing those ads. He estimates this could unlock 10x the market opportunity for developers because instead of monetizing just the small percentage of users who make purchases, they can now monetize their entire audience through advertising.

**ALEX**: The Q&A session revealed some really interesting

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
──────────
# Beta Finch Podcast Script - Uber Q1 2026 Earnings

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that matter. I'm Alex.

**JORDAN:** And I'm Jordan. Today we're breaking down Uber's Q1 2026 earnings, and wow - this was a quarter that really showed the breadth of what Uber has become.

**ALEX:** Absolutely, Jordan. And before we dive in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. Now, let's get into these numbers because they were genuinely impressive. Uber delivered 21% year-over-year growth in gross bookings - that's the total value of all transactions on their platform.

**ALEX:** And what I love about this quarter is how balanced the growth was. Mobility hit 20% growth with record margins, Delivery grew 23% driven by grocery and retail, and here's the kicker - Freight returned to growth for the first time in nearly two years.

**JORDAN:** That Freight turnaround is huge, Alex. That's been a drag on their numbers for a while. But the real standout for me was the profitability story. Non-GAAP earnings per share jumped 44% year-over-year - that's more than twice as fast as their bookings growth.

**ALEX:** Exactly! And they returned a record $3 billion to shareholders through buybacks this quarter. But let's talk about some of the strategic milestones because there were some big ones.

**JORDAN:** Oh absolutely. They crossed 50 million Uber One members - that's their subscription service - and hit 10 million drivers and couriers globally. CEO Dara Khosrowshahi mentioned that Uber One members now account for over 50% of their total bookings and spend three times more than non-members.

**ALEX:** That subscription moat is becoming really powerful. They added 20 million Uber One members in just one year, going from 30 million to 50 million. And speaking of strategic moves, they made some big announcements at their GO-GET event.

**JORDAN:** Right - they're expanding into hotel bookings through a partnership with Expedia, adding 700,000 hotels to the platform. It's a classic Uber move - they're already huge in airport trips, which represent about 15% of their mobility bookings, so hotels are a natural extension.

**ALEX:** And the numbers support this strategy. Khosrowshahi mentioned that 40% of US riders take trips outside their home city, and globally they had over 1.5 billion trips happening outside users' home cities last year. That's a massive travel audience to tap into.

**JORDAN:** But let's talk about what's really driving growth in their core business - insurance cost savings. This is huge for their US operations, Alex.

**ALEX:** Absolutely. CFO Balaji Krishnamurthy said they expect hundreds of millions in insurance savings this year. And here's the key - they're passing those savings back to consumers through lower prices, which is driving trip acceleration, especially in California markets like LA and San Francisco.

**JORDAN:** The elasticity story is working. Lower prices are translating directly to more trips, and LA - which had the biggest insurance headwinds over recent years - is now seeing significantly better growth trends than the rest of California and the country.

**ALEX:** Now, we have to talk about autonomous vehicles because that dominated a lot of the Q&A session. They have over 30 AV partners now and their autonomous mobility trips grew more than 10x year-over-year.

**JORDAN:** And they're on track to be live in up to 15 cities by year-end. But what's interesting is how they're positioning this not as a threat to their driver network, but as expanding the entire market. Khosrowshahi pointed out that in San Francisco and LA, where

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: ENERGY (https://betafinch.com/groups/ENERGY)
──────────
**BETA FINCH PODCAST SCRIPT**

---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into EOG Resources' first quarter 2026 earnings call. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks, Alex. And wow, what a quarter for EOG! They're definitely benefiting from some major geopolitical tailwinds, but there's a lot more substance here than just riding the oil price wave.

**ALEX:** Absolutely. Let's start with the numbers because they're pretty impressive. EOG generated $1.8 billion in adjusted net income and $1.5 billion in free cash flow for the quarter. They returned nearly $950 million to shareholders through dividends and buybacks. Jordan, what jumped out at you?

**JORDAN:** The cash flow generation is remarkable, especially when you consider they're projecting a record $8.5 billion in free cash flow for the full year 2026. But here's what I found fascinating - they're maintaining their $6.5 billion capital budget while increasing oil production guidance by 2,000 barrels per day and NGL production by 6,000 barrels per day. That's capital discipline in action.

**ALEX:** That's a great point about capital discipline. They're essentially reallocating capital from natural gas assets to oil-weighted assets within the same budget. CEO Ezra Yacob was pretty clear about this being a response to current market dynamics - oil prices surging due to the Iran conflict while natural gas prices remain soft.

**JORDAN:** Right, and let's talk about that geopolitical situation because it's driving a lot of their strategy. The conflict has removed an estimated 900 million barrels from global markets through June 2026, and EOG's management seems to believe this sets up a higher oil price floor going forward, even after the conflict resolves.

**ALEX:** The international expansion story is interesting too. They've got operations starting up in both the UAE and Bahrain. During the Q&A, management mentioned they're seeing strong partnerships with ADNOC and BAPCO, and they expect initial results from these exploration programs in the second half of 2026.

**JORDAN:** And their marketing strategy is really paying dividends - literally. They have 250,000 barrels per day of export capacity out of Corpus Christi, which gives them flexibility to price crude domestically or link to Brent pricing. Plus, their Cheniere LNG contract is expanding to 420,000 BTUs per day, with pricing linked to either JKM or Henry Hub at their election.

**ALEX:** That pricing flexibility is huge in volatile markets. CFO Ann Janssen mentioned they've been able to sell multiple cargoes at attractive pricing thanks to that export capacity. It's like having optionality built into their business model.

**JORDAN:** Speaking of Ann Janssen, let's talk shareholder returns because this is where things get really interesting. They're committed to returning at least 70% of free cash flow this year, which would be a record. And they've been aggressive on buybacks - 3.2 million shares in Q1, plus another 2.3 million shares just in April.

**ALEX:** The buyback strategy seems pretty opportunistic. During the Q&A, there was this great exchange about being tactical versus having a ratable program throughout the year. Management seems confident they're finding value in their own stock, even with oil prices elevated.

**JORDAN:** What I found telling was CEO Yacob's comment about potentially building some cash on the balance sheet during this upcycle to prepare for countercyclical investments when prices eventually pull back. That's exactly what they did with acquisitions like Encino

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
──────────
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we cut through the noise to bring you what matters most from corporate earnings calls. I'm Alex, and joining me as always is my co-host Jordan.

JORDAN: Hey everyone! Today we're diving into Disney's Q2 2026 earnings call, and wow - this was Josh D'Amaro's first call as CEO, so there was a lot to unpack.

ALEX: Absolutely. And before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

JORDAN: Right, so let's get into the numbers first. Disney posted solid results - revenue grew 7%, total segment operating income up 4%. They actually outperformed their own guidance for the quarter, which is always nice to see.

ALEX: Yeah, and what really caught my attention was the streaming business. Disney+ revenue growth actually accelerated from 11% in Q1 to 13% in Q2. That's the opposite of what we're seeing from some other streaming players who are hitting growth walls.

JORDAN: Exactly! And it wasn't just subscriber volume driving that growth - it was both rate increases AND more subscribers. Plus they had double-digit advertising revenue growth. The integrated Disney+ and Hulu experience seems to be helping with retention too.

ALEX: Now, the parks business - Disney Experiences - that was interesting. Revenue up 7%, operating income up 5%, but there were some headwinds. Jordan, can you break down what's happening there?

JORDAN: Sure. So they're dealing with two main challenges: reduced international visitation to US parks, and the impact of Universal's Epic Universe opening, which is pulling some attendance away. Domestic park attendance was actually down 1% in the quarter. But here's the key - Hugh Johnston, the CFO, said they expect these headwinds to ease in the back half of the year as they lap these impacts.

ALEX: And they're still investing heavily in growth. They just opened World of Frozen at Disneyland Paris and launched the Disney Adventure cruise ship in Asia. D'Amaro mentioned they have more projects underway globally than at any time in Disney's history.

JORDAN: That ambitious expansion is really part of D'Amaro's bigger vision. He kept talking about Disney+ becoming the "digital centerpiece" of the company - not just a streaming service, but a hub that connects everything Disney does.

ALEX: Right, and this is where it gets really interesting from a strategic standpoint. D'Amaro is talking about creating a more connected Disney experience across streaming, sports, games, and physical experiences. Think about it - someone watches a Disney movie, then visits a theme park, buys merchandise, plays games - each touchpoint reinforces the others.

JORDAN: It's all about lifetime value. He specifically mentioned that their biggest opportunity might be reducing churn on Disney+. If they can keep subscribers engaged longer, that flows through to everything else.

ALEX: The technology piece was fascinating too. They're going heavy on AI across multiple areas - hyper-personalized recommendations, better ad targeting, even precision labor forecasting at the theme parks to optimize staffing.

JORDAN: And they're experimenting with short-form content and vertical video to meet younger audiences where they are. D'Amaro specifically called out Gen Alpha as important for Disney's future.

ALEX: Now, one thing that came up multiple times in the Q&A was about Disney's portfolio - specifically whether they'd consider selling off some assets. Hugh Johnston was pretty clear that they view their entertainment networks as "brands with studios" rather than just distribution platforms, and separating them would be complex without creating much value.

JORDAN: Yeah, and on ESPN, they're

This episode includes AI-generated content.

More earnings analysis: https://betafinch.com
Groups: CHIPS (https://betafinch.com/groups/CHIPS), AI_LEADERS (https://betafinch.com/groups/AI_LEADERS)
──────────
**BETA FINCH PODCAST SCRIPT**

---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we decode the quarterly reports so you don't have to. I'm Alex, and joining me as always is Jordan. Today we're diving into AMD's absolutely stellar Q1 2026 results that had Wall Street buzzing.

But before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

Jordan, AMD just dropped some seriously impressive numbers. Walk us through the headline figures.

**JORDAN:** Alex, these results were nothing short of spectacular. AMD crushed expectations with $10.3 billion in revenue - that's 38% growth year-over-year. But here's the kicker - they're guiding for $11.2 billion in Q2, which would be 46% year-over-year growth. Their data center business is absolutely on fire, hitting a record $5.8 billion, up 57% from last year.

**ALEX:** And the profitability story is even better, right? I saw some incredible cash flow numbers.

**JORDAN:** Exactly! Free cash flow more than tripled to a record $2.6 billion - that's 25% of revenue. Earnings per share jumped 43% to $1.37. Lisa Su called it "a clear inflection in our growth trajectory and a structural shift in our business." Data center is now their primary growth driver, which is a massive change from just a few years ago.

**ALEX:** Now, the really interesting story here seems to be what AMD is calling the "Agentic AI" revolution. Jordan, they literally doubled their server CPU market size projection in just six months. How does that happen?

**JORDAN:** It's pretty remarkable, Alex. Back in November at their analyst day, they projected the server CPU market would grow at about 18% annually to around $60 billion by 2030. Now they're saying it'll grow at over 35% annually, reaching more than $120 billion by 2030.

Lisa Su explained it perfectly - as AI adoption scales and you get more inference workloads and AI agents, you need dramatically more CPU compute for orchestration, data processing, and managing these AI workloads. It's not just about the GPUs anymore.

**ALEX:** And AMD is positioned perfectly for this, aren't they? They're seeing massive growth in both their server CPUs and their AI accelerators.

**JORDAN:** Absolutely. Their EPYC server CPU business grew over 50% year-over-year, and they're guiding for over 70% growth in Q2. They're gaining market share against Intel while also benefiting from this expanding market. Plus, they landed some massive AI partnerships - they announced deals with Meta for up to 6 gigawatts of AMD Instinct GPUs and expanded their OpenAI partnership.

**ALEX:** Six gigawatts? That's... that's a lot of computing power. Put that in perspective for our listeners.

**JORDAN:** To put it simply, that's enough power to run a small city! These are multi-year, multi-billion dollar commitments. AMD is becoming a core infrastructure partner for the world's biggest AI companies. And the exciting part is Lisa Su mentioned they're seeing demand forecasts exceeding their initial plans, with visibility all the way down to which specific data centers these chips are going into.

**ALEX:** Now, it wasn't all perfect news. There were some headwinds mentioned, particularly around memory costs and China. Can you break that down?

**JORDAN:** Right, so memory prices are inflating across the industry, which is impacting both costs and consumer demand. AMD expects this to hurt PC and gaming demand in the second half of the year. They also saw their AI GPU revenue decline slightly in Q1 due to lower China sales, though that's more of a geographic mix shift than a fundamen

This episode includes AI-generated content.

# Beta Finch Podcast Script: Pfizer Q1 2026 Earnings

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the latest corporate results. I'm Alex, and joining me as always is Jordan. Today we're unpacking Pfizer's Q1 2026 earnings call, and folks, there's quite a bit to unpack here.

Before we dive in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. And what a quarter this was for Pfizer! They really came out swinging with some impressive numbers and some game-changing legal developments. Should we start with the headline figures?

**ALEX:** Absolutely. Pfizer reported Q1 revenues of $14.5 billion, which actually exceeded their own expectations. That's a 2% operational increase overall, but here's the kicker - if you strip out their COVID products, the underlying business grew about 7% operationally. That's solid growth in a challenging environment.

**JORDAN:** And the earnings story is even better. They hit $0.75 in adjusted diluted earnings per share, again beating expectations. What really caught my attention though was their launched and acquired products - these grew 22% operationally to $3.1 billion in the quarter. That's the portfolio transformation strategy Albert Bourla has been talking about really starting to pay off.

**ALEX:** Speaking of transformative developments, we need to talk about the elephant in the room - or should I say, the legal victories in the room. Pfizer had two major legal wins that could reshape their entire growth trajectory post-2028.

**JORDAN:** Right, the Vyndamax patent settlement is huge. This drug, which treats a rare heart condition, was facing generic competition, but now Pfizer has extended exclusivity until mid-2031. We're talking about a $6 billion-plus product here, Alex. CEO Albert Bourla said this "has the potential to change the growth profile of the company significantly post-2028."

**ALEX:** And then there's the Belgian court ruling on their Comirnaty contracts with EU countries. CFO Dave Denton called this "a positive for future EPS and cash flow." These aren't just minor legal technicalities - these are major financial game-changers that give Pfizer much clearer visibility into their cash flows.

**JORDAN:** Which brings us to one of the most interesting parts of the call - Pfizer's new confidence about their post-2028 growth trajectory. Bourla said they now expect a "5-year period of high single-digit revenue CAGR" starting in 2029. That's a pretty bold statement, especially when you consider they're still navigating some significant patent cliff challenges.

**ALEX:** Let's break that down for listeners. CAGR stands for Compound Annual Growth Rate. So Pfizer is essentially saying that starting in 2029, they expect to grow revenues at a high single-digit percentage rate - so probably 7-9% annually - for five straight years. That would be impressive for any pharma company, let alone one coming off the COVID revenue peaks.

**JORDAN:** And the foundation for that confidence seems to be their pipeline and their recent acquisitions. They mentioned having about 20 pivotal study starts planned this year, 8 key data readouts, and 4 regulatory decisions. That's a packed R&D calendar. They're particularly excited about their oncology portfolio, especially after the Seagen acquisition.

**ALEX:** The oncology story is fascinating. They reported 20% year-over-year growth in their Seagen products, and they've got some potentially blockbuster readouts coming. There's Padcev for bladder cancer, which affects over 600,000 patients globally, and their multiple myeloma drug Elrexfio just hit positive Phase III results.

**JORDAN:** Don't forget about the obesity play with their Metsera acquisition.

This episode includes AI-generated content.

**Beta Finch Podcast Script: Duke Energy Q1 2026 Earnings**

---

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we turn complex financial reports into clear insights. I'm Alex, and with me as always is Jordan. Today we're diving into Duke Energy's first quarter 2026 results, and folks, this utility giant is making some serious moves in the data center boom.

Before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. And wow, what a quarter for Duke Energy! They posted adjusted earnings per share of $1.93, beating last year's $1.76. But honestly, the earnings beat is just the appetizer here - the main course is this massive data center story that's unfolding.

**ALEX:** Absolutely right, Jordan. Duke is sitting at the epicenter of this AI infrastructure buildout. They've now secured 7.6 gigawatts of electric service agreements with data centers - that's adding another 2.7 gigawatts just this quarter alone. To put that in perspective, we're talking about enough power for millions of homes.

**JORDAN:** And what I love about Duke's approach here is how they're protecting existing customers. CEO Harry Sideris really emphasized this - these new data center contracts include minimum demand provisions, credit support, refundable capital advances, and termination charges. Basically, if these big tech companies want Duke's power, they're paying their fair share upfront.

**ALEX:** That's crucial because one of the biggest concerns investors have had about this data center boom is whether utilities will stick existing customers with the bill for all this new infrastructure. Duke seems to have that covered. In fact, they're saying these incremental volumes will actually benefit all customers over time as system costs get spread over a larger base.

**JORDAN:** Speaking of customer benefits, Alex, did you catch those two major announcements that total over $5 billion in customer savings? First, they struck a multi-year deal to monetize up to $3.1 billion in clean energy tax credits through 2028, with proceeds flowing back to customers. And second, they got regulatory approval to combine their two Carolina utilities, which should save customers $2.3 billion through 2040.

**ALEX:** Those are massive numbers, Jordan. And the timing is perfect because Duke has rate cases pending in the Carolinas right now. CFO Brian Savoy mentioned they might use some of these savings as tools to mitigate rate increases. Smart move - it shows regulators they're serious about keeping rates affordable even as they invest heavily in new infrastructure.

**JORDAN:** Let's talk about that infrastructure investment because it's staggering. Duke is executing a $103 billion capital plan - that's with a "B" - and they're funding it through these strategic asset sales. They closed $2.8 billion from selling a minority stake in their Florida utility to Brookfield, plus another $2.5 billion from selling their Tennessee gas business to Spire.

**ALEX:** Over $5 billion in proceeds that strengthen their balance sheet while funding growth. And they're not just building for data centers - they're adding 14 gigawatts of generation over the next five years. A big chunk of that is natural gas plants, including a 1.4 gigawatt facility in South Carolina that just got approved.

**JORDAN:** The nuclear angle is interesting too, Alex. Duke operates the largest regulated nuclear fleet in the nation, and they just got approval to extend the life of their Robinson Nuclear Plant. That's their second plant to reach this milestone, and they plan to seek similar extensions for all their remaining reactors. Nuclear provides about $600 million in annual tax credits to customers, so keeping these plan

This episode includes AI-generated content.

**Beta Finch Podcast Script**

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're breaking down Vertex Pharmaceuticals' Q1 2026 earnings call - and wow, Jordan, this was packed with updates.

JORDAN: Absolutely, Alex. But before we jump in, let me get our mandatory disclaimer out of the way. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

ALEX: Thanks, Jordan. Now, let's talk Vertex. This biotech giant just delivered some impressive numbers - $2.99 billion in total revenue for Q1, representing 8% growth year-over-year. But what really caught my attention was how they're diversifying beyond their cystic fibrosis cash cow.

JORDAN: Right, and that diversification story is really the headline here. CEO Reshma Kewalramani emphasized that their newer products - KASJEVY and GERNAVICS - drove about 25% of their total revenue growth. That's a company successfully expanding its footprint beyond a single therapeutic area.

ALEX: Let's break down those newer products. KASJEVY, their gene editing therapy, brought in $43 million in Q1 revenue with over 500 patients now having started treatment. Then there's GERNAVICS for pain management at $29 million in revenue. But the real excitement seems to be around their renal pipeline, particularly something called Povitacicept or "Povi."

JORDAN: Oh, the Povi data was genuinely impressive, Alex. They just completed what Kewalramani called their fastest regulatory submission in company history - 27 days from database lock to filing. The Phase III interim results for IgA nephropathy showed a 52% reduction in proteinuria, which is a key marker doctors watch. Kewalramani described the results as "sparkling from top to bottom."

ALEX: And they're not stopping there with renal disease. They're positioning this as potentially their fourth major franchise alongside CF, blood disorders, and pain. The addressable patient population across their renal programs could be in the hundreds of thousands when you add up all the different kidney diseases they're targeting.

JORDAN: What I found interesting in the Q&A was when analyst Jessica Fye asked about renal potentially rivaling their CF business in size. Kewalramani didn't shy away from that comparison. She pointed out that while each kidney disease is rare, they're "common rare diseases" - IgA nephropathy alone affects about 150,000 patients in North America and Europe.

ALEX: The numbers definitely support the growth story. Non-GAAP earnings per share came in at $4.47, up from $4.06 the previous year. They're managing expenses well while investing heavily in these new areas - SG&A expenses were up 30% year-over-year, but that's driven by commercial investments in pain and renal programs.

JORDAN: Speaking of investments, they spent about $344 million buying back shares in Q1, showing they're returning cash to shareholders while still funding growth. They ended the quarter with $13 billion in cash and investments, so they've got plenty of firepower.

ALEX: Now, it wasn't all good news. They had to discontinue their VX-522 program for CF patients who can't benefit from their current modulators. Kewalramani explained they couldn't overcome tolerability issues related to lung inflammation, likely from the delivery mechanism.

JORDAN: That's about 5,000 patients who still can't be helped by Vertex's current CF portfolio. But Kewalramani was adamant they're not giving up on this population. She said their "commitment to CF is absolute and steadfast" and they'll go back to the drawing board on delivery methods.

ALEX: Let's talk guidance. They're sticking with their full-year revenue guidance of $12.95 to $13.10 billion, repre

This episode includes AI-generated content.